The Pharma X Next Conference 2026 is proud to welcome Serena Saggini, Director at Sophos Biotech S.r.l., Italy, as a distinguished speaker and award winner at one of the most influential global gatherings for pharmaceutical and biotechnology leaders.
With more than 25 years of leadership experience in the global pharmaceutical and life sciences industry, Serena Saggini has built a remarkable reputation as a strategic leader known for driving innovation, commercial excellence, and sustainable growth across multiple therapeutic areas including Oncology, Rare Diseases, Biotechnology, Central Nervous System (CNS) disorders, Cardiology, Nephrology, and Women’s Health.
Throughout her extensive career, Serena has held senior leadership positions at internationally recognized pharmaceutical companies including Sanofi Genzyme, Ferring Pharmaceuticals, GSK, and Schering-Plough. Her expertise spans business development, market access, commercial strategy, sales leadership, marketing transformation, and organizational growth, making her one of the respected voices in the modern pharmaceutical landscape.
Currently serving as Director at Sophos Biotech S.r.l., Serena plays a critical role in driving commercial growth in the oncology sector while contributing to the broader business development and strategic expansion initiatives of the company. Her leadership continues to support innovation-focused healthcare solutions aimed at improving patient outcomes and strengthening sustainable access to advanced therapies.
In recognition of her outstanding contribution to the pharmaceutical and biotechnology sector, Serena Saggini will also be honored during the Pharma X Next Awards 2026 with the prestigious award title:
“Excellence in Pharma Industry for Strategic Leadership in Oncology & Biotech”
This recognition highlights her long-standing impact on pharmaceutical commercialization, patient-centric innovation, strategic leadership, and the advancement of oncology and biotech-focused healthcare solutions globally.
About Sophos Biotech S.r.l.
Sophos Biotech S.r.l. is a specialized oncology-focused company dedicated to supporting healthcare professionals through high-quality pharmaceutical products and value-driven healthcare services. The company is committed to improving patients’ lives by developing and marketing a focused oncology portfolio while promoting the appropriate and sustainable use of medicines.
Sophos Biotech’s mission is centered around contributing to effective, innovative, and sustainable therapies that can create meaningful improvements in healthcare outcomes. By focusing on scientific quality, patient-centered solutions, and strong collaboration with clinicians and healthcare institutions, the company continues to strengthen its role within the pharmaceutical industry.
Since 2023, Sophos Biotech has been part of the SPA – Società Prodotti Antibiotici S.p.A. group, further enhancing its capabilities and market presence within the healthcare and pharmaceutical ecosystem.
Exclusive Written Interview with Serena Saggini
Serena Saggini on the Future of Pharma Commercial Excellence, Patient-Centricity, and Digital Transformation
At the Pharma X Next Conference 2026, Serena Saggini shared a compelling vision for the future of pharmaceutical commercialization — one built on integration, data quality, and genuine patient-centricity.
According to Serena, the pharmaceutical industry is entering an era where traditional siloed operations are no longer sustainable, especially in highly complex areas such as oncology and rare diseases. She believes that commercial, medical, and market access teams must operate as a unified ecosystem, supported by reliable data and aligned around a shared objective: delivering meaningful outcomes for patients.
She emphasizes that patient-centricity must evolve beyond being a corporate slogan. Instead, companies need to deeply understand and address the real-world needs of patients, ensuring that every strategic decision contributes to equitable healthcare access and improved patient experiences.
Discussing the concept of commercial excellence in today’s pharmaceutical and biotech landscape, Serena explains that success is no longer defined by the performance of isolated departments. True commercial excellence now depends on how effectively organizations integrate functions, transform high-quality data into actionable insights, and create strategies that generate long-term value for both patients and healthcare systems.
She highlights that the pharmaceutical industry is currently facing major challenges in bringing innovative therapies — particularly in oncology and rare diseases — to market. As therapies become increasingly personalized and scientifically advanced, regulatory pathways and reimbursement systems are under growing pressure.
In Serena’s view, one of the industry’s biggest priorities should be ensuring that innovation not only reaches the market, but also reaches patients equitably. She stresses that sustainable healthcare systems and equitable patient access must remain central to the commercialization strategy of every pharmaceutical company.
Digital transformation and artificial intelligence are also playing a defining role in shaping the future of pharma commercialization. Serena believes that the real competitive advantage does not come from simply having more data, but from having access to reliable, relevant, and actionable information that supports faster and smarter decision-making.
She notes that AI is increasingly enhancing data analysis, improving segmentation, and enabling better strategic alignment across commercial, medical, and market access functions. However, she underlines that AI should augment human judgment rather than replace it. In a rapidly evolving pharmaceutical landscape, companies must not only make the right decisions, but make them quickly enough to create meaningful impact.
For emerging leaders in the pharmaceutical industry, Serena advocates a leadership style rooted in adaptability, integrity, and purpose. She encourages future leaders to combine scientific understanding with commercial and digital expertise while maintaining a strong focus on patient impact.
She also believes that professional growth comes from stepping outside one’s comfort zone and embracing challenging opportunities. Above all, Serena stresses the importance of long-term thinking, collaboration, and sustainable value creation — principles that are becoming increasingly critical in an industry where performance must go hand in hand with equitable access to care.
As the pharmaceutical sector continues to evolve through innovation, digital transformation, and increasing healthcare complexity, Serena Saggini’s perspective offers a timely reminder that the future of pharma leadership will depend not only on scientific advancement, but also on the industry’s ability to integrate data, strategy, and humanity into one cohesive vision.
She received congratulations and recognition from Anas Jawed, CEO of Next Business Media, for her remarkable leadership and contribution to advancing the global pharmaceutical and biotechnology ecosystem.
About Pharma X Next Conference 2026
Pharma X Next Conference 2026 is a premier international platform designed to bring together pharmaceutical executives, biotechnology innovators, healthcare leaders, researchers, policymakers, digital transformation experts, and commercial strategists from across the global life sciences ecosystem.
The conference serves as a hub for knowledge exchange, collaboration, and innovation, focusing on some of the industry’s most important themes including commercial excellence, AI in pharma, digital transformation, market access, patient-centric innovation, oncology advancements, biotech growth, and the future of healthcare delivery.
Through keynote sessions, panel discussions, strategic networking opportunities, and prestigious industry awards, Pharma X Next Conference 2026 aims to recognize leaders and organizations that are driving meaningful change and creating long-term value across the pharmaceutical and biotechnology sectors.
The event continues to attract influential decision-makers and thought leaders who are shaping the future of global healthcare and advancing innovation for better patient outcomes worldwide.
The conference organizers have also officially announced the dates for the 2nd Edition of Pharma X Next Conference, which will take place on 11–12 March 2027, bringing together global pharma leaders, biotech innovators, healthcare executives, and industry experts once again for another impactful edition focused on the future of healthcare and life sciences.
Website: https://pharmaxnext.com/
